

MSAs were chosen based on having high AIDS prevalence. Persons at risk for HIV infection to be interviewed for NHBS include men who have sex with men (MSM), injecting drug users (IDU), and heterosexuals at increased risk of HIV (HET). A brief screening interview will be used to determine eligibility for participation in the behavioral assessment.

The data from the behavioral assessment will provide estimates of (1) behavior related to the risk of HIV and other sexually transmitted diseases, (2)

prior testing for HIV, (3) and use of HIV prevention services.

All persons interviewed will also be offered an HIV test, and will participate in a pre-test counseling session. No other federal agency systematically collects this type of information from persons at risk for HIV infection. These data have substantial impact on prevention program development and monitoring at the local, state, and national levels.

CDC estimates that NHBS will involve, per year in each of the 25 MSAs, eligibility screening for 50 to 200 persons and eligibility screening plus

the behavioral assessment with 500 eligible respondents, resulting in a total of 37,500 eligible survey respondents and 7,500 ineligible screened persons during a 3-year period. Data collection will rotate such that interviews will be conducted among one group per year: MSM in year 1, IDU in year 2, and HET in year 3. The type of data collected for each group will vary slightly due to different sampling methods and risk characteristics of the group.

Participation of respondents is voluntary and there is no cost to the respondents other than their time.

ESTIMATE OF ANNUALIZED BURDEN HOURS

Respondent	Form	Number of respondents	Number of responses per respondent	Average burden per response (hours)	Total burden (in hours)
Persons Screened	Eligibility Screener	15,000	1	5/60	1,250
Eligible Participants:	Behavioral Assessment MSM	4,167	1	30/60	2,084
Eligible Participants:	Behavioral Assessment IDU	4,167	1	54/60	3,750
Eligible Participant	Behavioral Assessment HET	4,167	1	39/60	2,709
Peer Recruiters:	Recruiter Debriefing	4,167	1	2/60	139
Total Annualized Burden	9,932

LeRoy Richardson,

Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2013-28280 Filed 11-25-13; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Health Resources and Services Administration

Renewal of the Advisory Committee on the Maternal, Infant and Early Childhood Home Visiting Program Evaluation

ACTION: Notice.

Authority: Section 511(g)(1) of Title V of the Social Security Act (42 U.S.C. 711 et seq.), as amended by Section 2951 of the Patient Protection and Affordable Care Act of 2010 (Pub.L. 111-148). The Committee is governed by provisions of Public Law 92-463, as amended, (5 U.S.C. App.2), which sets forth standards for the formation and use of advisory committees.

SUMMARY: ACF and HRSA announce the renewal of the Advisory Committee on the Maternal, Infant and Early

Childhood Home Visiting Program Evaluation to provide advice to the Secretary of Health and Human Services (“the Secretary”) on the design, plan, progress, and findings of the evaluation required under the Act.

FOR FURTHER INFORMATION CONTACT: T’Pring Westbrook, Administration for Children and Families; tpring.westbrook@acf.hhs.gov.

SUPPLEMENTARY INFORMATION: Section 511(g) of the Affordable Care Act of 2010 mandates an Advisory Committee to review, and make recommendations on, the design and plan for the evaluation required under the Act. To comply with the authorizing directive and guidelines under the Federal Advisory Committee Act (FACA), a charter has been filed with the Committee Management Secretariat in the General Services Administration (GSA), the appropriate committees in the Senate and U.S. House of Representatives, and the Library of Congress to establish the Advisory Board as a non-discretionary federal advisory committee. The charter was filed on January 27, 2013.

Objectives and Scope of Activities

The purpose of the Committee is to provide advice and make recommendations to the Secretary of Health and Human Services, through the Assistant Secretary, ACF and Administrator, HRSA, with respect to

the design, plan, progress and results of the evaluation.

Membership and Designation

The Committee shall consist of up to 25 members appointed by the Secretary. Members shall be experts in the areas of program evaluation and research, education, and early childhood development. Members shall be appointed as Special Government Employees. The committee shall also include ex-officio members representing ACF, HRSA and other agencies of the federal government designated by the Secretary as ex-officio members. The ACF Assistant Secretary and HRSA Administrator each shall recommend nominees for Co-Chairs of the Committee.

Members shall be invited to serve from the date of appointment through March 31, 2015; such terms are contingent upon the renewal of the Committee by appropriate action prior to its termination.

Administrative Management and Support

Coordination, management, and operational services shall be provided by ACF, with assistance from HRSA.

A copy of the Committee charter can be obtained from the designated contacts or by accessing the FACA database that is maintained by the GSA Committee Management Secretariat. The

Web site for the FACA database is <http://fido.gov/facadatabase/>.

Naomi Goldstein,

Director, Office of Planning, Research, and Evaluation, ACF.

Rebecca Slifkin,

Director, Office of Planning, Analysis and Evaluation, HRSA.

[FR Doc. 2013-28324 Filed 11-25-13; 8:45 am]

BILLING CODE 4184-22-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0002]

Withdrawal of Approval of New Animal Drug Applications; Arsanilic Acid

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of a new animal drug application (NADA) for an arsanilic acid Type A medicated article at the sponsor's request because the product is no longer manufactured or marketed.

DATES: Withdrawal of approval is effective December 6, 2013.

FOR FURTHER INFORMATION CONTACT: John Bartkowiak, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9079, john.bartkowiak@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Fleming Laboratories, Inc., P.O. Box 34384, Charlotte, NC 28234 has requested that FDA withdraw approval of NADA 008-019 for PRO-GEN (arsanilic acid) Type A medicated article because the product, used to manufacture Type B and Type C medicated feeds, is no longer manufactured or marketed.

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 *Notice of withdrawal of approval of application* (21 CFR 514.116), notice is given that approval of NADA 008-019, and all supplements and amendments thereto, is hereby withdrawn.

Elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of this application.

Dated: November 20, 2013.

Bernadette Dunahm,

Director, Center for Veterinary Medicine.

[FR Doc. 2013-28255 Filed 11-25-13; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a stakeholder meeting hosted by the NIH Scientific Management Review Board (SMRB). The SMRB's Working Group on Approaches to Assess the Value of Biomedical Research Supported by NIH will present their findings and conclusions regarding optimal approaches to assessing the value of biomedical research supported by the NIH.

The NIH Reform Act of 2006 (Pub. L. 109-482) provides organizational authorities to HHS and NIH officials to: (1) Establish or abolish national research institutes; (2) reorganize the offices within the Office of the Director, NIH including adding, removing, or transferring the functions of such offices or establishing or terminating such offices; and (3) reorganize, divisions, centers, or other administrative units within an NIH national research institute or national center including adding, removing, or transferring the functions of such units, or establishing or terminating such units. The purpose of the SMRB is to advise appropriate HHS and NIH officials on the use of these organizational authorities and identify the reasons underlying the recommendations.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Scientific Management Review Board (SMRB).

Date: December 18, 2013.

Time: 10:00 a.m. to 12:00 p.m. (EST).

Agenda: The teleconference will focus on the findings and recommendations of the Working Group on Approaches to Assess the Value of Biomedical Research Supported by NIH. The full Board will review and vote on the draft report from the Working Group. SMRB members will also be presented with a new charge regarding science, technology,

engineering, and mathematics (STEM) education. Time will be allotted on the agenda for public comment. To sign up for public comment, please submit your name and affiliation to the contact person listed below by December 17, 2013. Sign-up will be restricted to one sign-up per person. In the event that time does not allow for all those interested to present oral comments, any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

The toll-free number to participate in the teleconference is 800-369-1872, and the passcode will be 7887272.

Place: National Institutes of Health, Office of the Director, NIH, Office of Science Policy, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Juanita Marner, Office of Science Policy, Office of the Director, NIH, National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, smrb@mail.nih.gov, (301) 435-1770.

The draft meeting agenda and other information about the SMRB will be available at <http://smrb.od.nih.gov>.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxis, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS).

Dated: November 20, 2013.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-28266 Filed 11-25-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.